Comment
doi: 10.1016/S1474-4422(23)00034-0.
Extended-interval dosing of natalizumab in NOVA - Authors' reply
Affiliations
- PMID: 36804085
- DOI: 10.1016/S1474-4422(23)00034-0
Item in Clipboard
Comment
Extended-interval dosing of natalizumab in NOVA - Authors' reply
Lancet Neurol.
2023 Mar.
No abstract available
Conflict of interest statement
JFF reports personal compensation for consulting activities from Biogen and Octave, and compensation (paid to his institution) for data safety monitoring or advisory boards from Biogen, Genentech, and Novartis. NC and GK are employees of and hold stock or stock options in Biogen.
Comment on
-
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25. Lancet Neurol. 2022. PMID: 35483387 Clinical Trial.
-
Extended-interval dosing of natalizumab in NOVA.Lancet Neurol. 2023 Mar;22(3):199-200. doi: 10.1016/S1474-4422(23)00032-7. Lancet Neurol. 2023. PMID: 36804084 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
